Connect with us

Uncategorized

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial – News-Medical.Net

A large clinical trial, known as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2), is set to take place, which aims to test monoclonal…

Published

on

The coronavirus disease 2019 (COVID-19) pandemic continues to spread worldwide, with a new highly infectious strain identified in the UK, causing surges of new cases. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 can cause mild to severe illness, while some do not experience any symptoms at all.
A large clinical trial, known as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2), is set to take place, which aims to test monoclonal antibody…

Click here to view the original article.

Continue Reading
Advertisement